Stage 2 of 4
Retatrutide trials and access
Clinical trials, expanded access, and their requirements.
Retatrutide is investigational. It is not sold by any pharmacy, it cannot be compounded, and no telehealth service can prescribe it. Access information below includes clinical trials, expanded access, and the approval timeline, with links to Lilly and ClinicalTrials.gov.
The three routes
- Route 1
Join a clinical trial
Free drug under medical monitoring, with a placebo arm in most studies. Enrollment for most of the Phase 3 program has closed; the live list below shows what is still open.
How trial sign-up works → - Route 2
Ask about expanded access
Since August 3, 2026, a clinician can request retatrutide from Lilly for an adult with refractory obesity and a BMI of at least 35 kg/m², at least two serious complications, and no eligible trial. Case by case, not guaranteed.
Read the criteria → - Route 3
Wait for approval
Lilly plans to file in the first quarter of 2027. A standard review takes about ten months, so the first decision lands in late 2027 or early 2028, followed by pricing and coverage.
See the timeline →
Trials near you
Select your state to see studies with nearby sites, then open a study for its eligibility criteria and contact details from ClinicalTrials.gov.
11 active retatrutide studies · 2 marked recruiting
2 studies match your filters
- RecruitingPhase 3 · NCT07165028
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Metabolic Dysfunction-Associated Steatotic Liver Disease · Eli Lilly and Company
- Listed locations
- 34 countries · 563 sites worldwide
- Registry record updated
- 2026-10-08
Check eligibility and site contacts for NCT07165028 →Show all listed countries
Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, France, Germany, Hong Kong, Hungary, India, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom, United States
- RecruitingPhase 2 · NCT07467447
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
Obesity · Hudson Biotech
- Listed locations
- China · 1 site worldwide
- Registry record updated
- 2026-03-12
Registry data is cached for up to 24 hours. A study marked recruiting may have individual sites that are closed; the study team confirms eligibility and availability. “Closed to new participants” studies are running but no longer enrolling. Each listing on ClinicalTrials.gov carries the eligibility criteria, the site list and a contact for enrollment. How trial participation works.
Options that do not provide access
Products sold as retatrutide are not the pharmaceutical product supplied in the trials.
Online vials
Sold as “research use only”. Unverified purity and amount, no medical oversight, and the FDA is issuing warning letters to sellers that name retatrutide.
Read about online vials →Compounding pharmacies
Compounders may only copy approved drugs. The July 2026 advisory vote covered six other peptides, and it changes nothing until a final rule.
Read about compounding pharmacies →Telehealth
Platforms can prescribe approved GLP-1 drugs such as tirzepatide and semaglutide today. None can prescribe retatrutide.
Read about telehealth →Read next
Retatrutide Cost per Month and How to Access It
Every legitimate route to retatrutide today, open trials updated daily, Lilly's expanded access criteria, and what it may cost once approved.
Updated October 16, 2026
How to Sign Up for a Retatrutide Clinical Trial
Check current sponsor and registry listings. SYNERGY-OUTCOMES is recruiting; TRIUMPH-7 is active but no longer recruiting.
Updated September 8, 2026
Retatrutide FDA Approval Timeline 2026-2028
Lilly plans a Q1 2027 BLA filing. TRIUMPH-1, -2 and -3 have reported. Approval window late 2027–28.
Updated October 2, 2026
When Will Retatrutide Be Available?
Lilly plans a Q1 2027 U.S. submission. There is no confirmed approval or commercial launch date.
Updated September 8, 2026
Are Peptides Legal in 2026? Inside the FDA 503A Vote Result
FDA advisory votes do not add peptides to the final compounding list. Current U.S. rules, evidence limits and GLP-1 distinctions.
Updated September 8, 2026
Grey Market Retatrutide: Risks, Dangers, and What You Should Know
Research labels and purity claims do not establish product equivalence, approved dosing or legal exemptions.
Updated September 8, 2026